Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells

Sepantronium bromide (YM155), originally developed against the anti-apoptotic protein survivin, performed exceptionally well in pre-clinical and phase I clinical trials. However, in phase II trials of several cancer types including breast cancer it performed poorly. Additionally, no definitive corre...

Descripción completa

Detalles Bibliográficos
Autores principales: Wani, Tasaduq H., Surendran, Sreeraj, Mishra, Vishnu S., Chaturvedi, Jaya, Chowdhury, Goutam, Chakrabarty, Anindita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173358/
https://www.ncbi.nlm.nih.gov/pubmed/30323901
http://dx.doi.org/10.18632/oncotarget.26096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173358/
https://www.ncbi.nlm.nih.gov/pubmed/30323901
http://dx.doi.org/10.18632/oncotarget.26096

Ejemplares similares